pharma · HNSCC · Squamous Cell Carcinoma of the Skin · PHIO
Phio Pharmaceuticals
Phio Pharmaceuticals is a pharma organization headquartered in King of Prussia, USA. It trades on NYSE under ticker PHIO. Primary therapeutic focus areas include HNSCC, Squamous Cell Carcinoma of the Skin. NovaPharmaNews
King of Prussia, USA HQ
2012 Founded
15 Employees
Public company Type
PHIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- King of Prussia, USA
- Founded
- 2012
- Employees
- 15
- Programs
- 2
- Drugs
- 0
- Patents
- 39
PH-762
Phase 1 · small molecule · Squamous Cell Carcinoma of the Skin
PH-762 for Squamous Cell Carcinoma of the Skin is a Phase 1 program (small_molecule) at Phio Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code PHIO-762-2301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Phio Pharmaceuticals
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Squamous Cell Carcinoma of the Skin
- Status
- active
- Trials
- 1